TELA Bio is a publicly-traded regenerative medicine company focused on soft tissue products used in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery.

With headquarters in Malvern, Pennsylvania, TELA Bio is a publicly traded (Nasdaq: TELA) regenerative medicine company addressing unmet needs in the $2.0+ billion soft tissue reconstruction market in the United States. The company offers a portfolio of advanced reinforced tissue matrices that improve clinical outcomes and reduce overall cost of care.

TELA Bio markets the OviTex Reinforced Tissue Matrix for surgical procedures including hernia repair and abdominal wall reconstruction. The Company also recently launched Ovitex PRS, a reinforced tissue matrix specifically designed for reconstructive breast surgery. The Company’s hybrid soft tissue repair products are made from synthetic and biologic materials, offering physicians a differentiated alternative designed to limit stretch, reduce long-term complications associated with other technologies, promote
tissue healing and ultimately improve patient outcomes while generating cost savings for the healthcare system.

Transaction Summary

  • In November 2019, TELA Bio successfully completed an initial public offering and raised gross proceeds of $52.0 million.